Drug General Information
Drug ID
D05JAC
Drug Name
Linagliptin
Synonyms
Linagliptin; BI 1356; Ondero; 668270-12-0; Tradjenta; BI-1356; Linagliptin (BI-1356); UNII-3X29ZEJ4R2; BI-1356-BS; CHEMBL237500; 3X29ZEJ4R2; CHEBI:68610; C25H28N8O2; Linagliptin
Drug Type
Small molecular drug
Indication Coronavirus Disease 2019 (COVID-19) Phase 3 [1]
Other Indication Type 2 diabetes Approved [2]
Therapeutic Class
Antiviral Agents
Structure
Download
2D MOL

3D MOL

Formula
C25H28N8O2
InChI
1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
InChIKey
LTXREWYXXSTFRX-QGZVFWFLSA-N
CAS Number
CAS 668270-12-0
PubChem Compound ID
Target
Target(s) HUMAN dipeptidyl peptidase 4 (DPP-4) Target Info Inhibitor [3], [4]
Linagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor. Evidence suggests that DPP4i modulate inflammation and exert anti-fibrotic activity. These properties are of potential use for halting progression to the hyperinflammatory state associated with severe COVID-19.
References
1 ClinicalTrials.gov (NCT04371978) Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19. U.S. National Institutes of Health.
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 208026
3 DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19 Diabetes Metab Res Rev. 2020 Apr 26.
4 Effects of Dipeptidyl Peptidase 4 Inhibition on Inflammation in Atherosclerosis: A 18 F-fluorodeoxyglucose Study of a Mouse Model of Atherosclerosis and Type 2 DiabetesAtherosclerosis. 2020 Apr 10. pii: S0021-9150(20)30194-5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.